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InﬂammationPI3Ks regulate several key events in the inﬂammatory response to damage and infection. There are four Class I
PI3K isoforms (PI3Kα,β,γ,δ), three Class II PI3K isoforms (PI3KC2α, C2β, C2γ) and a single Class III PI3K. The
four Class I isoforms synthesise the phospholipid ‘PIP3’. PIP3 is a ‘second messenger’ used by many different
cell surface receptors to control cell movement, growth, survival and differentiation. These four isoforms have
overlapping functions but each is adapted to receive efﬁcient stimulation by particular receptor sub-types.
PI3Kγ is highly expressed in leukocytes and plays a particularly important role in chemokine-mediated
recruitment and activation of innate immune cells at sites of inﬂammation. PI3Kδ is also highly expressed in
leukocytes and plays a key role in antigen receptor and cytokine-mediated B and T cell development,
differentiation and function. Class III PI3K synthesises the phospholipid PI3P, which regulates endosome-
lysosome trafﬁcking and the induction of autophagy, pathways involved in pathogen killing, antigen processing
and immune cell survival. Much less is known about the function of Class II PI3Ks, but emerging evidence
indicates they can synthesise PI3P and PI34P2 and are involved in the regulation of endocytosis.
The creation of genetically-modiﬁed mice with altered PI3K signalling, together with the development of
isoform-selective, small-molecule PI3K inhibitors, has allowed the evaluation of the individual roles of Class I
PI3K isoforms in several mouse models of chronic inﬂammation. Selective inhibition of PI3Kδ, γ or β has each
been shown to reduce the severity of inﬂammation in one or more models of autoimmune disease, respiratory
disease or allergic inﬂammation, with dual γ/δ or β/δ inhibition generally proving more effective. The inhibition
of Class I PI3Ksmay therefore offer a therapeutic opportunity to treat non-resolving inﬂammatory pathologies in
humans. This article is part of a Special Issue entitled Phosphoinositides.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Overview of the inﬂammatory response
There have been several excellent reviews detailing the role of PI3Ks
in various immune cells [1–5]. The aim here is to place some of this
knowledge in the broader context of the inﬂammatory response and
to focus on the roles played by individual PI3K isoforms, particularly
isoforms of the Class I family.
Inﬂammation is generally deﬁned as the body’s response to infection
and damage [6]. A successful inﬂammatory response removes the initial
irritant and repairs any tissue damage that has occurred. Unfortunately,
several pathological conditions are sustained by a non-resolving inﬂam-
mation that leads to chronic pain and disability e.g., rheumatoid arthritis
(RA); systemic lupus erythematosus (SLE); chronic obstructive pulmo-
nary disease (COPD); Crohn’s disease; ulcerative colitis. Even tumours
are considered by some to represent ‘open wounds’ that are fuelled
by an inﬂammatory response. It is therefore important to understandnositides.
.T. Hawkins),
. This is an open access article underthe causes of non-resolving inﬂammation and how they might be
treated [7,8].
2. The role of innate immune cells
The course of an inﬂammatory response depends on the precise
nature of the initial stimulus and where in the body it is located.
Although this involves a highly co-ordinated response from many
different types of immune and non-immune cells [9], several common
principles can be discerned (Fig. 1). The initial phase of acute inﬂamma-
tion is co-ordinated by the innate immune system. This phase generally
lasts from minutes to hours and involves the detection of pathogens/
damage by resident immune cells (mostly macrophages, dendritic
cells, mast cells and “innate lymphoid” cells – lymphoid cells without
rearranged antigen receptors [10]), activation of platelets, activation of
the complement cascade and the release of signals from damaged or
infected host cells. This creates a complex mixture of soluble inﬂam-
matory mediators that communicate the source of infection to
neighbouring capillaries. Here they perform overlapping and individual
roles to alter vascular tone and permeability and also locally to re-model
the endothelium to drive the ﬁrst wave of recruitment of furtherthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. An overview of the inﬂammatory response.
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key mediators in this initial recruitment are chemoattractants and
chemokines which stimulate leukocyte attachment, extravasation and
chemotaxis towards the source of inﬂammation [12–16]. Ideally, resi-
dent and inﬁltrating immune cells are stimulated in this inﬂammatory
milieu to eliminate the foreign invaders by deploying a battery ofmicro-
bicidalweapons and the inﬂammation proceeds towards a rapid resolu-
tion. Macrophages then arrive to mop up apoptosed cells and other
debris. Less ideally, the innate immune response at least buys time for
the adaptive immune response to be brought into play.
3. The development of B and T-lymphocytes
The adaptive immune response operates on a time scale of days to
weeks and essentially attempts to create a tailored response that de-
pends on the speciﬁc nature of the invading pathogen. The chief clue
to mounting an appropriate response is the context in which antigens
are presented to themain components of the adaptive immune system,
the B and T lymphocytes. B-lymphocyte development in the bone mar-
row creates a repertoire of naïve B-cells each of which expresses a dif-
ferent functional antigen receptor (BCR) capable of recognising foreign
molecules in their ‘native’ state e.g., proteins or polysaccharides [17].
T-lymphocyte development is completed in the thymus and creates
analogous repertoires of either CD4+ T-helper cells (Th) or CD8+ cyto-
toxic T-cells (CTLs)which also possess antigen receptors (TCRs) [18,19],
but these receptors are adapted to recognise foreign peptides onlywhen
bound to either MHC-I (CD8+-CTLs) or MHC-II (CD4+-Th) molecules
[20]. Mature lymphocytes then circulate through the various vessels of
the vascular and lymphatic systems and through secondary lymphoid
tissues (lymph nodes and spleen). Amajor task of the adaptive immune
system and its anatomical structure is to promote effective encounters
between foreign antigens and the small numbers of lymphocytes capa-
ble of recognising them.4. The T cell response
Professional antigen-presenting cells (APCs; dendritic cells, B-cells
and macrophages) phagocytose extracellular pathogens/proteins,
creating small, foreign peptides (via phagolysosomal digestion), some
of which are then presented on their cell surface bound to MHC-II
[20,21]. Dendritic cells play the major role in carrying antigen/MHC-II
complexes created at an initial site of infection, through the lymph ves-
sels, to secondary lymphoid tissues, where they are engaged by naïve
CD4+ T-helper cells. If the combination of peptide/MHC-II and other
surface molecules on the activated APCs are recognised by the TCR
and its co-receptors on the CD4+ T cell with appropriate afﬁnity, and
the correct local cytokines are present, a sequence of T cell differentia-
tion and clonal expansion is initiated towards various effector subsets
(eg Th1, Th2, Tfh, Th17) [22]. The type of effector cells produced is guid-
ed by the precise nature of the cytokine cues available (e.g., IL-12 pro-
motes differentiation towards Th1; IL-4 promotes differentiation
towards Th2; IL-6 promotes differentiation towards Th-17) which is in
turn determined by the initial experience of the APCs themselves (i.e.
the nature of the substance or pathogen encountered). The response
rapidly evolves to include other autocrine and paracrine contributions
(e.g. IL-2) and a characteristic feature is that paracrine signals generated
from one lineage characteristically inhibit differentiation towards an-
other (e.g. IFN-γ produced by Th1 cells inhibits differentiation towards
Th2). These different effector subsets then shape the evolving adaptive
immune response both locally, in lymphoid tissues, and at sites of
inﬂammation (through their release into the vasculature and homing
to sites of inﬂamed endothelium). Differentiation towards Th1 is a char-
acteristic response to intracellular parasites (e.g., viruses and some
types of bacteria and protozoa), its main functions being to help recruit
and prime CTLs (see below) and to generate cytokines (eg IFN-γ) which
promote the development of phagocytic macrophages [23]. Differentia-
tion towards Th2 is a typical response to extracellular parasites and
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producing plasma cells (eg through the production of IL-4 and CD40-
mediated cell contact) and also leads to the production of cytokines
(e.g., IL-10, IL-13)which aremajor factors in the recruitment and activa-
tion of eosinophils and basophils [23]. Tfh cells are also specialised to
provide help to activated B cells and play an important role in
supporting antibody class-switching and afﬁnity-maturation during
the germinal centre reaction (see below) [24]. Th-17 cells, which are
characteristically seen as pro-inﬂammatory cells produced in response
to extracellular bacteria and fungi, generate cytokines (eg IL-17)
which contribute to the recruitment and activation of neutrophils at
sites of inﬂammation, usually close to epithelial barriers [25].
Cells infected with intracellular pathogens (e.g. viruses) present for-
eign peptides (created through proteosomal digestion) bound toMHC-I
[20]. These peptides can be recognised as antigens by the TCR/co-
receptors on appropriately primed CTLs, which are then able to kill
the presenting cell though the release of pore-forming proteins and
digestive enzymes [26]. All cells possess MHC-I molecules and are
potential targets for attack by CTLs. Infected APCs (e.g. dendritic cells)
can present antigen/MHC-I in parallel with antigen/MHC-II and help
polarise Th cells towards Th1 cells, which in turn recruit CTLs, leading
to their priming and proliferation through antigen/MHC-I interactions
and the generation of supporting cytokines (IFN-γ and IL-2).
5. The B cell response
Appropriate encounters between B cells and native antigens lead to
their differentiation into antibody-producing plasma cells, usually
termed the ‘humoral response’. If the encounter between the BCR
and cognate antigen is sufﬁciently strong to induce extensive BCR
crosslinking, or is supported by TLR engagement, then differentiation
towards plasma cells can occur without T-cell help (‘T-cell independent
response’) [27]. T-cell independent antibodies are often generated
against the polysaccharide coat of certain bacteria, with both marginal
zone B cells in the spleen (MZ-B cells) and B1 cells in pleural and peri-
toneal cavities playing a prominent role. In most cases, however, an
effective antibody response requires T-cell help (‘T-cell dependent
response’) [27]. Follicular B cells that have encountered antigen (for
example when presented on the surface of follicular dendritic cells)
can endocytose the BCR-antigen conjugates and present foreign pep-
tides bound to MHC-II. These activated B cells can then recruit Th cells
(mostly Th2 or Tfh) which possess a TCR recognising the particular
peptide/MHC-II complex to form an ‘immunological synapse’ [20].
Cell-cell interactions and cytokines produced by the Th cells then
shape the differentiation of the B cells to plasma cells in specialised
niches of lymphoid follicles called germinal centres, which are designed
to maximally promote clonal B cell expansion and selection [24]. These
are the sites at which cytokine-driven antibody class switching
(e.g., IgM to IgG, IgA and IgE) and afﬁnity maturation occur.
Successful T-cell dependent immune responses generate memory B
cells and memory T cells that allow much faster and more effective re-
sponses if and when the same antigens are encountered subsequently
[24,28,29]. Previously generated IgE also coats FcRs on long-lived mast
cells [30], basophils [31] and also neutrophils [32], supporting a rapid
response to a further encounter with cross-linking antigen.
6. Suppression of the immune response
There is an increasing realisation of the important role that so-called
‘suppressor’ cells play in maintaining an appropriately poised immune
response (‘peripheral tolerance’). Although the development and differ-
entiation of both B and T cell lineages is remarkably effective at remov-
ing cells that recognise self-antigens (‘central tolerance’), some auto-
reactive cells escape deletion and represent a potential threat to the
host [33]. The activation of these cells is countered by suppressor cells,
which effectively raise the threshold at which activation of B- andT-cells occurs. The most clearly understood of these sub-sets are the
so-called Tregs, which are produced centrally in the thymus (nTregs)
and can also be induced during an immune response (iTregs) [34].
These cells can inhibit the proliferation and function of effector cells
(eg CTLs) by sequestering critical cytokines required for clonal expan-
sion (e.g. IL-2), producing suppressive cytokines (eg IL-10) or killing
cells directly through the release of granzyme or perforin [34]. There
is also increasing evidence for important suppressor cell populations
in the B [35] and myeloid cell lineages (MDSCs) [36], though these are
currently less well understood.
7. Autoimmunity
Whilst the immune system is generally extremely effective in com-
bating a huge variety of pathogens and challenges to the body’s integri-
ty, it does also carry signiﬁcant capacity for ‘self-harm’. Although
remarkably effective, mechanisms of central and peripheral tolerance
can fail, leading to the generation of auto-reactive B and T-cells [33],
the generation of auto-antibodies and/or inappropriate activation of in-
nate immune cells [37,38]. The ensuing chronic inﬂammation does not
resolve properly because the source of the inﬂammation is the host it-
self. This process is thought to be at the core of several major autoim-
mune diseases, such as SLE, RA and type 1-diabetes. There are also
several common and debilitating conditions where the inﬂammatory
response appears to ‘over react’, causing more damage than appears
necessary to remove the initial insult, classic cases being allergic asthma
(predominantly Th2-driven,with involvement ofmast cells, eosinophils
and neutrophils) and chronic obstructive pulmonary disease (COPD;
predominantly a Th1 response, with activation of CTLs, macrophages
and neutrophils). In most of these diseases, the underlying causes are
extremely complex, involving multiple interactions between genes
and the environment [37,38].
8. PI3K signalling
Phosphoinositide 3-kinases (PI3Ks) are enzymes which catalyse the
phosphorylation of one ormore inositol phospholipids in the 3-position
of the inositol ring (see Fig. 2). Both the substrates and products of these
reactions are membrane-captive phospholipids and the action of PI3Ks
is to generate speciﬁc molecular messengers in the membranes upon
which they act. There are eight PI3Ks in mammalian cells that are
classiﬁed into three families; four Class I isoforms (PI3Kα,β,γ,δ), three
Class II isoforms (PI3KC2α,β,γ) and a single Class III isoform [3,39].
9. Class I PI3K signalling pathways
Class I PI3Ks selectively phosphorylate phosphatidylinositol 4,5-
bisphosphate (PI(4,5)P2) to form phosphatidylinositol 3,4,5-trisphos-
phate (PI(3,4,5)P3, usually referred to as ‘PIP3’) (Fig. 2). Class I PI3Ks
are regulated directly or indirectly by cell surface receptors and play im-
portant roles in the early signal transduction events that ﬂow from the
activation of these receptors [39,40]. PIP3 is synthesised at the plasma
membrane and in very early endocytic structures and regulates the
localisation and activity of numerous effector proteins through binding
to conserved domains, the best characterised of which are a sub-family
of PH-domains [41] (Fig. 3). PIP3 is dephosphorylated at the 3-position
to re-form the substrate of Class I PI3K, PI(4,5)P2, by the enzyme PTEN
[42]. PIP3 can also be de-phosphorylated at the 5-position by the SHIP
family of phosphatases (SHIP1/2) to form PI(3,4)P2 [43,44]. PTEN and
SHIP2 are ubiquitously expressed but SHIP1 is preferentially expressed
in cells of the haematopoetic lineage and is thought to play an important
role in limiting PIP3 levels when recruited to inhibitory receptors [45].
PI(3,4)P2 can be dephosphorylated at the 4-position by InsPP4A/B to
form PI3P [46]. The rapid appearance of PIP3 and PI(3,4)P2 are charac-
teristic signs of Class I PI3K activation, with little accumulation of PI3P
(presumably because active 3-phosphatases remove this phospholipid
Fig. 2. Reactions catalysed by PI3Ks. PI3Ks transfer the γ-phosphate of ATP to the 3-position on the inositol ring. Class I PI3Ks selectively phosphorylate PI(4,5)P2. Class II PI3Ks
phosphorylate both PI and PI4P. Class III PI3K is speciﬁc for phosphorylation of PI. Phospholipids are shown with C18:0 (stearoyl) and C20:4 (arachidonoyl) acyl chains, which are the
most abundant chains found in these lipids in mammals.
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accurately measuring these lipids, there are still relatively few studies
that describe changes in their levels on cell activation. This is particular-
ly true in differentiated subsets of primary immune cells, particularly in
the B and T cell lineage, where it is difﬁcult to isolate sufﬁcient cells for
analysis.The activation of Class I PI3Ks creates a complex signalling web based
on multiple interactions between PIP3 and PI(3,4)P2 and their effector
proteins (Fig. 3) [39,40]; there are probably 10-30 PH-domain containing
effector proteins that respond to the generation of these two lipids in a
given target cell [48]. Many of these effectors bind both PIP3 and PI(3,4)
P2 (e.g., PKB, PRex), some prefer PIP3 only (e.g. Grp1, BTK) and a few
Fig. 3. The Class I PI3Ks signalling network.
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ential functions [49]. This idea is obviously important in evaluating the
role of PIP3 5-phosphatases, such as SHIP1, whichmight be viewed either
as terminating a PIP3-speciﬁc response or directing a PI(3,4)P2-speciﬁc
response [50]. However, the precise role of PI(3,4)P2 in Class I PI3Ks
responses still remains largely undeﬁned.
Some of the key cellular processes regulated by Class I PI3K sig-
nalling include growth, movement and differentiation. Phosphoryla-
tion and activation of the serine kinase PKB (also known as AKT)
appears to be a ubiquitous response to activation of Class I PI3K
(and is often used as a surrogate read out of this pathway) [51].
One of the many substrates of PKB is the Rheb-GAP, TSC1/2, which
PKB can phosphorylate and inhibit, leading to activation of the cen-
tral regulator of cell growth, mTORC1. Mutations in and around the
PI3K/PKB/mTORC axis are amongst the most prevalent in human
cancers, illustrating its importance in growth factor signalling [52].
It should be noted however, that PI3K/PKB is not always the critical
regulator of mTORC1 activity, for example mTORC1 regulates the
switch to aerobic glycolysis during CTL activation and clonal expan-
sion independently of PI3K/PKB [53].
PKB can also phosphorylate and inhibit the nuclear localisation of
FOXO transcription factors, which are critical regulators of lymphocyte
development and differentiation [54]. Members of the Tec kinase family
(e.g. BTK in B cells and ITK in T cells) also play prominent roles in leuko-
cytes through regulating the PLC/DAG/Ca2+-driven transcription of key
cytokines [55]. PIP3/PI(3,4)P2 also regulates many of the elements of
actin polymerisation and the accompanying changes in cell shape that
underlie cell movement and phagocytosis, including several GEFs and
GAPs for small GTPases of the Rac and Arf families [56–58].
In any speciﬁc context of cell regulation, Class I PI3Ks are always
activated alongside other intracellular signalling pathways and
interact with them at multiple levels to create a speciﬁc cellular
response. Partly because of this, PI3K signalling is often observed
to inﬂuence other cellular pathways variably, depending on the
cell type and receptors activated, leading to apparently ‘conﬂicting’ re-
sults. For instance within immune cells it is particularly complicating
that other central signalling pathways (e.g., Erk, p38MAPK), key down-
stream responses (egNFκ-B-dependent transcription) or even upstreamactivating receptors (e.g. TLRs) appear to be variably associated with
Class I PI3K activation.
10. Class I PI3K isoforms
The Class I PI3Ks themselves are heterodimers containing one type
of regulatory subunit tightly bound to one catalytic subunit (Fig. 4).
There are four isoforms, PI3Kα,β,γ and δ, that are named after the
catalytic subunit they contain. They are usually sub-classiﬁed into two
further groups, Class IA and Class IB, based on their structure and general
mode of regulation [39].
Class IA PI3Ks contain one of ﬁve homologous regulatory subunits,
p85α/p55α/p50α, p85β or p55γ, bound to a single p110α, p110β, or
p110δ catalytic subunit, to form ﬁve potential heterodimers for each
catalytic subunit, known as ‘PI3Kα’, ‘PI3Kβ’ or ‘PI3Kδ’, respectively, i.e.
ﬁfteen potential heterodimers in total. Thus far, no clear subunit prefer-
ences have been described between the regulatory and catalytic
subunits of the Class 1A PI3Ks, and this is an underexplored concept.
Class I B PI3Ks contain one of two homologous subunits, p101 or p84
(also known asp87PIKAP). p101 or p84 speciﬁcally bind to a single p110γ
catalytic subunit to form two potential heterodimers, p101/p110γ or
p84/p110γ, both known as ‘PI3Kγ’.
Each of the Class I PI3K isoforms catalyses the same reaction and,
though there may be signiﬁcant differences in their kinetic parameters,
the main distinction between them appears to be in their adaptation to
upstream regulation by receptor transduction pathways [39,59]. The
Class I PI3Ks are soluble enzymes and are activated by a combination
of factors that both recruit the enzyme to the membrane in which
their substrate resides (which is usually envisaged to be the inner leaﬂet
of the plasma membrane) and trigger conformational changes that
make them more efﬁcient catalysts. Key factors are the binding of the
regulatory subunits to speciﬁc signals generated by cell-surface recep-
tors, the conformational changes that ensue from these interactions
and the binding of membrane-captive small GTPases to the Ras Binding
Domains (RBDs) of the catalytic subunits [60].
The Class I B isoform, PI3Kγ, is differentially expressed amongst cells
and tissues, with highest levels of expression in the myeloid lineage
(eg neutrophils, macrophages and mast cells), though important
Fig. 4. Regulation of Class I PI3K isoforms.
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T-cells, endothelial cells and cardiac myocytes [61]. PI3Kγ is adapted to
regulation by GPCRs that signal through Gi-family heterotrimeric
G-proteins; the important regulatory elements here are direct binding
of Gβγ subunits to the heterodimer (the precise interaction sites have
yet to be mapped) and synergistic activation by GTP-Ras (Fig. 4) [62].
Interestingly, p84 and p101 appear to be differentially expressed, with
p84 being the dominant regulatory subunit in mast cells [63]. Both
in vitro and model cell studies have suggested that p84/p110γ dimers
may be more sensitive to activation by GTP-Ras while p101/p110γ di-
mers may be more sensitive to activation by Gβγ, implying differential
adaptation to upstream inputs [64,65]. Further, both reconstitution
studies in mast cells [63] and a recent comparison of the phenotypes
of mouse neutrophils lacking either p84 or p101 (Deladeriere et al,
Science Signaling in press), suggest p101/p110γ and p84/p110γ are
designed to regulate different cell responses, even in the same cell. The
molecular explanation for this remarkable speciﬁcity is unknown but it
seems likely that p84- and p101-speciﬁc interactions must generate
signalling complexeswith distinct properties, possibly involving spatially
segregated ‘nano-domains’ of PIP3. An additional level of regulation of
the p84/p110γ dimer has also been described recently in mast cells,
where PKCβ has been shown to phosphorylate p110γ downstream of
the FcεR, decoupling the regulatory and catalytic subunits [66].
The Class IA isoforms PI3Kα and PI3Kβ are relatively ubiquitous in
their expression but PI3Kδ is mostly conﬁned to expression in cells of
the myeloid and lymphoid lineages [3,5]. The presence of high levels
of PI3Kδ is thus a characteristic of most immune cells. All Class IA
PI3Ks are adapted to regulation by receptors that directly or indirectly
signal via protein tyrosine kinases, with one or both SH2 domains in
the regulatory subunits binding to phosphotyrosines within speciﬁc
recognition motifs (eg ‘YXXM’) [60]. Early work deﬁned important
PI3K-recruitmentmotifs in the cytoplasmic tails of growth factor recep-
torswith intrinsic protein tyrosine kinase activity (e.g. PDGF-R, CSF1-R).It has however, been surprisingly difﬁcult to identify the analogous sites
in signalling adaptors downstream of receptors which indirectly
employ protein tyrosine kinases (e.g. Src, Tec, Syk) in their signalling
networks e,g, FcγRs and antigen receptors on immune cells. This is
probably because there is signiﬁcant redundancy in these networks
(which means multiple ‘knock-in’ mutations need to be created to
fully deﬁne Class IA PI3K recruitment and activation).
Phosphotyrosine-SH2-domainmediated interactions serve to both re-
cruit PI3Ks to the membrane and to relieve regulatory subunit-mediated
inhibition of the catalytic domain [60]. Each Class IA regulatory subunit
contains two functional SH2 domains but the shorter versions (p55α,
p50α and p55γ) lack a potential small GTPase regulatory domain
(the BCR homology domain) and N-terminal SH3 domain. The functional
differences between these different regulatory subunits are unclear but
are likely to involve differential recruitment to upstream signalling
complexes, possibly mediated through BCR and SH3 domain-mediated
contacts. Notwithstanding differences between the regulatory subunits,
each of the Class IA PI3K catalytic subunits is thought to be able to bind
to each of the p85/55/50 regulatory subunits, apparently limiting the
potential for catalytic isoform-selective activation. However, some impor-
tant distinctions have emerged recently that start to explain the observed
differential sensitivities of some of these heterodimers to upstream
regulation.
The RBD domain of p110α is selective for GTP-Ras and this interac-
tion is important for efﬁcient activation of PI3Kα heterodimers [67].
By contrast, the RBD of p110β is selective for GTP-Rac or GTP-Cdc42
and this is important for activation of PI3Kβ [67]. The selectivity or, in-
deed, necessity of small GTPase interaction with the RBD of p110δ is
currently unclear and warrants further investigation. Elegant structural
studies have recently revealed that the same regulatory subunit makes
different contacts with each catalytic subunit, creating differences in
their sensitivity to SH2-phosphotyrosine-mediated release from regula-
tory subunit inhibition [60,68]. PI3Kβ can also be directly activated by
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mapped [69]. The sensitivity and scale of activation of PI3Kβ by Gβγ is
much lower than the analogous activation of PI3Kγ, but contributes
signiﬁcantly to a very substantial and synergistic activation of PI3Kβ
bybothGβγ andphosphotyrosinepeptides both in vitro and in response
toGPCRs in cellularmodels [70]. The extent towhichGβγs alonemay be
important for physiological activation of PI3Kβ is difﬁcult to establish,
however, because of the difﬁculty imposed by the requirement to inter-
fere speciﬁcally with SH2 domain-directed input in only this isoform.
There is also good evidence that GTP-Rab5 can bind p110β via a novel
interaction that has yet to be precisely deﬁned [71].
Thus, one can envisage that, upon the appearance of appropriate
activating phosphotyrosines, each of the Class IA enzymes undergoes
SH2-domain engagement in proportion to their relative levels of
expression (favouring PI3Kδ in immune cells), but speciﬁc regulatory
subunit-catalytic subunit interactions (perhaps dual engagement of
SH2 domains being required for maximal activation of PI3Kα and δ),
and the simultaneous presence of GTP-Ras (favouring PI3Kα) or GTP-
Rac/Cdc42 (favouring PI3Kβ) and/or the presence of GPCR-liberated
Gβγ subunits (favouring PI3Kβ) will result in a differential contribution
of each isoform to the generation of PIP3.
Although the above discussion has focussed on differences between
Class I PI3K isoforms, it should be noted that in many, perhaps most,
contexts of cell regulation more than one PI3K contributes to the ‘PIP3
response’ e.g. [72–74]. Even in scenarios where it is claimed a particular
PI3K isoform plays a ‘non-redundant’ role in a particular cell response,
usually on thebasis of thedifferential impact of genedeletion or isoform
selective inhibitors, there is insufﬁcient detail to delineate the precise
contribution that each isoform makes at different doses of agonist.
This is especially the case when surrogate readouts of Class I PI3K activ-
ity are measured, which may have a non-linear relationship to PI3K
activity (eg PKBphosphorylation). Further, the precise expression levels
of each isoform are almost never known in terms of molecularFig. 5. Regulation ofequivalents, precluding a ‘true’ assessment of isoform-selective engage-
ment by upstream receptors. Layered upon these considerations, Gi-
coupled GPCRs characteristically stimulate protein tyrosine kinases of
the Src/Tec families in their signalling networks, thus engaging Class IA
aswell as Class IB PI3Ks e.g. [75]. Further, there are now several examples
where receptor tyrosine kinase signalling stimulates autocrine loops
which engage GPCRs, again entangling both Class IA and IB PI3Ks [76,
77]. When each receptor/cell combination is then considered in the con-
text of an inﬂammatory response, involving a huge array of mediators
and cell types, it is clear thatwe are far frombeing able to build a convinc-
ing understanding of the role of individual PI3Ks in inﬂammation from a
consideration of the elemental properties of the enzymes and pathways
alone.
11. Class II and Class III PI3Ks
Class III PI3K phosphorylates phosphatidylinositol (PI) to form phos-
phatidylinositol 3-phosphate (PI3P) at speciﬁc intracellular locations
(Fig. 5), such as endosomes and early autophagocytic structures, and
regulates the fate and function of these structures through binding to
distinct effector domains (eg FYVE and PX domains)(Fig. 6) [78,79].
There is only a single Class III PI3K catalytic subunit (also known as
Vps34 by relation to its initial discovery in S. cerevisiae) that binds to a
putative protein kinase (p150 or Vps15), which is involved in its regula-
tion. Class III PI3K/p150 can be isolated from cells in distinct complexes
with other proteins (beclin, UVRAG, ATG14) that determine its precise
location and function. Complexes containing ATG14 are involved in
the induction of autophagosomes [80,81], whilst complexes containing
UVRAG are involved in endo-lysosomal transport [82]. The molecular
details of how these complexes function and indeed how Class III PI3K
activity is regulated are still poorly understood (largely because of the
signiﬁcant problems involved in recreating these complexes from
recombinant proteins in vitro) but are likely to involve multipleClass II/III PI3Ks.
Fig. 6. Signalling through Class II/III PI3Ks.
889P.T. Hawkins, L.R. Stephens / Biochimica et Biophysica Acta 1851 (2015) 882–897phosphorylation events catalysed by upstream kinases (eg AMPK,
mTORC1) [82]. It also seems highly likely that further components of
Class III PI3K complexes have yet to be discovered.
Class II PI3Ks are even less well understood but accumulating
evidence suggests they are able to synthesise either PI3P or PI(3,4)P2 at
the plasma membrane or endosomes, at least in some circumstances in
response to receptor stimulation (Fig. 5) [83–86]. Presumably the gener-
ation of these lipids can trigger regulatory events analogous to those
which occur when the same lipids are synthesised by Class III/I PI3Ks.
12. Major roles for speciﬁc PI3Ks in the inﬂammatory response
Most of our information concerning PI3K isoform-speciﬁc roles
stems from the use of p110δ, p110γ and, more recently, p110β,
‘knock-out’, ‘conditional knock-out’ and ‘kinase-dead knock-in’ mice,Table 1
PI3K-selective inhibitors and mouse genetic models useful for evaluating PI3K isoform involve
Compound IC 50 (μM)
Class I PI3K
p110α p110β p110γ p110δ
BYL719 0.004 N1 0.25 0.29
A66 0.04 N12 N3 N1
TGX 221 ≅5 0.005 N10 0.1
IC 87114 N100 ≅5 ≅1 0.1
AS 605240 0.06 0.27 0.008 0.3
VPS34-IN1 8.04 21.44 2.649 1.90
Genetic model
Mouse +/− [221] KD/KD [76,116] KD/KD [225] KD/KD [92]
+/KD [222] −/− [76,116] −/− [88–90] −/− [91]
ﬂox/ﬂox [223] ﬂox/ﬂox [224] ﬂox/ﬂox [173]
The inhibitor data is drawn from several sources, see [4,5,87,205]. PI3Kα-selective inhibitors
promising reagent but less has been published on its properties. PI3Kβ-selective inhibitors: T
AZD6482 has improved drug-like properties but is less PI3K-selective. The PI3Kδ inhibitors: IC
tool although it has a relatively low selectivity over PI3Kα, particularly in vivo; AS252424 is mo
p110γ has a lower Km for ATP than the other p110s, the practice, that is sometimes described in
their individual Kms for ATP, although technically sound, tends to make p110γ-selective inh
inhibitors; VPS34-IN1 is the ﬁrst highly selective inhibitor that has been reported (WO pate
extensively characterized [94].
Genetic manipulation of PI3Ks in mice: kinase dead alleles are abbreviated to KD; +/− indica
Cre-conditional allele has been derived. Mouse Class II PI3K C2α has been targeted by the Sange
a ﬂoxed mTor allele are available from Jackson labs.together with highly selective p110δ, p110β and p110γ inhibitors
(Table 1) [1,3–5,87], though the p110γ-selective reagents generally
show poor cell-penetrance, making judgements over ‘selective’ doses
difﬁcult. Mice lacking a functional version of PI3Kγ [88–90] or PI3Kδ
[91,92], are viable and ‘healthy’ when bred under animal house condi-
tions and early studies indicated they had signiﬁcant defects in aspects
of both innate and adaptive immunity, driving a great deal of the
work in this ﬁeld. Mice lacking functional PI3Kβ are viable, but are
small [76]. The lack of functional PI3Kα is embryonic lethal and
therefore tissue-speciﬁc (‘conditional’) deletion or the use of hetero-
zygotes is necessary to delineate function [5]; further, p110α-
selective inhibitors with good cell-penetrance have generally been
unavailable in the public domain, meaning the speciﬁc function of
PI3Kα in immune cells is generally much less well understood.
Mice lacking functional Class III PI3K also die in the early embryoment in pathophysiological processes.






N10 N10 N10 0.025 N1
+/− [84] −/− [97] ﬂox/ﬂox [226] +/−[93] +/− [227]
ﬂox/ﬂox [84] ﬂox/ﬂox
: the BYL719 and A66 have signiﬁcant (0.58–0.25 μM) IC50s on PI4Kβ; INK1117 looks a
GX 221, although it has poor drug-like properties, remains an excellent tool; in contrast,
87114 remains an excellent tool. The PI3Kγ inhibitors: AS 605240 remains a widely used
re PI3Kγ-selective although more difﬁcult to synthesise and less widely available; because
the literature, of assaying an inhibitor with different p110s at ATP concentrations equal to
ibitors appear more selective than they may be in more cell-like environments. VPS34
nt 2012085815 A1; Cornella Taracdo, I., Harrington, E.M., Honda, A. and Keaney E.) and
tes that homozygous loss results in mice not surviving to adulthood; ﬂox/ﬂox indicates a
r/EUCOMM consortium andmice are available (PIK3C2atmla(EUCOM)Hmgu). Mice expressing
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selective catalytic site inhibitors should allow rapid progress in this
area [94,95]. Mice lacking PI3KC2α develop chronic renal failure
[96] and mice lacking PI3KC2β have not yet revealed phenotypes in
the immune system [97]; good selective inhibitors of these enzymes
are also not yet available.
The use of these genetic and pharmacological tools has allowed
rapid progress to be made in identifying key roles for PI3Ks in immune
cells [1,3–5,87].
13. Recruitment of innate immune cells
There is now a substantial body of evidence from both in vitro and
in vivo studies that suggests PI3Kγ plays an important role in the initial
signal transduction events downstream of Gi-coupled chemoattractant
and chemokine receptors (eg receptors for fMLP, C5a, IL-8, LTB4) that
lead to the extravasation andmigration of innate immune cells (eg neu-
trophils, monocytes, eosinophils) to sites of inﬂammation [56,57,88–90,
98–102]. Important cellular responses underlying this effect include the
regulation of selectin- and integrin-mediated adhesion and actin depen-
dent cell polarisation and chemokinesis [14,15,57]. Some of these
studies suggest different extents of PI3Kγ involvement and several
also implicate the co-involvement of PI3Kδ [103,104], presumably via
indirect activation of tyrosine kinases (e.g. src family kinases), possibly
mediated through engagement of adhesion receptors, such as integrins,
which allow the migrating cell to gain traction [57]. Studies in vivo also
suggest roles for PI3Kγ and δ in the inﬂamed endothelium [104,105].
The net result appears to be that loss of PI3Kγ blunts the initial recruit-
ment of innate immune cells to the site of inﬂammation but that loss of
both PI3Kγ and δ is more effective [105]. An interesting recent study has
also linked high Class I PI3K activity in neutrophils from COPD patients
with dysregulated chemotaxis [106].
14. Activation of innate immune cells
PI3Ksβ and δ play important roles in regulating the spreading and
activation of neutrophils and macrophages when they attach to various
surfaces, such as extracellular matrix, or large pathogens (e.g. fungi)
[76,107–109]. This activation characteristically leads to the secretion of
ROS and proteases downstream of protein tyrosine kinase signalling
induced by ligation of integrins and FcγRs. These signalling pathways
are similar to those downstream of antigen receptors, involving
Src-family tyrosine kinase phosphorylation of ITAM motifs in the Fc
γ-chain, the recruitment of Syk and Tec tyrosine kinases and the
tyrosine phosphorylation of multiple adaptors, though the speciﬁc
phosphotyrosines directly recruiting the SH2-domains in Class IA
PI3Ks are still unclear [110]. These Class I PI3Ks are also required for
efﬁcient phagocytosis of large antibody-opsonised particles but, inter-
estingly, they appear to be less important for phagocytosis and killing
of smaller, complement-opsonised bacteria [111–113]. Both PI3Kβ and
δ are also required for amaximal ROS response of neutrophils spreading
on immobilised immune complexes (a model of auto-antibody mediat-
ed host damage), but PI3Kβ is much more important at lower antibody
densities, possibly because it can more efﬁciently integrate GPCR-
induced Gβγ inputs arising from an autocrine LTB4 loop [76]. PI3Kγ
plays an essential role in chemoattractant and chemokine-mediated
ROS production and granule secretion in neutrophils and macrophages
in response to diverse receptors, including GPCRs, (eg C5a or formylated
peptides) [102,114,115] with signiﬁcant contributions also from PI3Kβ
in macrophages [116] and PI3Kδ in neutrophils [75]. A key feature of
Class I PI3K involvement in all of these responses is the activation of
Rac, which plays an essential role in assembling an active NADPH
oxidase complex and organising the actin cytoskeleton [114,117].
Neutrophil apoptosis and subsequent phagocytosis bymacrophages
is an important component of the resolution of inﬂammation. All of the
Class I PI3Ks appear to play ‘redundant’ roles in the regulation ofcytokine-mediated neutrophil survival, possibly via the regulation of
PKB [73].
Evidence on the role of Class I PI3Ks in the signalling pathways down-
streamof TLRs onmacrophages and dendritic cells is at present confusing,
with different publications suggesting this pathway can play either posi-
tive or negative roles in the production of pro-inﬂammatory cytokines
[118]. In macrophages, TLRs can induce the recruitment of Class IA
PI3Ks to phosphorylated YXXMmotifs in BCAP (previously identiﬁed as
a major signalling adaptor in B cells, see below) and this plays an
important role in down-regulating NF-κB driven transcription of pro-
inﬂammatory cytokines [118]. Further, in dendritic cells, loss of functional
PI3Kδ reduces TLR4 internalisation and relocation to the endosomes
in response to LPS, thus promoting the early-phase secretion of pro-
inﬂammatory cytokines (IL-6 and IL-12) and reducing the later-phase
secretion of anti-inﬂammatory cytokines (IL-10, IFN-β) [119]. PI3Kγ
also plays a signiﬁcant role in vivo in the chemokine-driven migration of
dendritic cells to draining lymph nodes and hence antigen presentation
to CD4+ T cells [120,121]. In other cell contexts, however, TLRs appear
to play a more important role as ‘primers’ of subsequent responses to
activating ligands, cf, TNFα-priming of GPCR-stimulated PI3Kδ-driven
PIP3 responses in human neutrophils [75,122].
PI3Kδ plays an important role in the protein tyrosine kinase-driven
signal transduction pathways stimulated by antigen-dependent cross-
linking of the FcεR1onmast cells, leading to calcium-stimulated granule
secretion and the release of important pro-inﬂammatory mediators,
such as histamine and adenosine [123]. Clustering of IgE-bound FcεRs
by antigen initiates a complex network of tyrosine kinase activities,
including Src family kinases and Syk, leading to the phosphorylation
of YXXMmotifs on the adaptor Gab2 and the recruitment and activation
of Class IA PI3Ks [124]. The release of adenosine also contributes to
sustained activation via purinergic (A3AR) receptor-stimulation of
PI3Kγ [77]. The use of transgenic mice and pharmacological inhibitors
has also implicated both PI3Kδ and γ isoforms in the migration and
activation of mast cells in vivo [74,77,123,125–129].
Natural killer lymphocytes (NK cells) are innate lymphoid cells
(see above). NK cells possess a collection of activatory and inhibitory
receptors which allow them to speciﬁcally engage and destroy cells
with low levels of MHC-I, which is a characteristic of foreign, unhealthy,
infected or cancerous cells. The role of both PI3Kγ and δ in NK cell
mediated homing and killing of target cells is currently confusing,
with data in vitro suggesting a more prominent role (eg in response to
CXCL12, CCL3, S1P) than appears in vivo [130,131].
The relative roles of PTEN, SHIP1/2 or other PIP3 phosphatases in reg-
ulating the action of Class I PI3K responses in innate immune cells are still
mostly unexplored [3,4,132]. However, SHIP1 clearly plays an important
role in regulating Class I PI3K activation in mast cells and macrophages
via recruitment to inhibitory receptors [133,134]. SHIP1has also been im-
plicated in generating an appropriate PIP3 signal for effective neutrophil
polarisation and chemotaxis (‘toomuch PIP3’ can induce strong adhesion
and inhibit effective front-back polarisation) [135]. A further mechanism
for the regulation of PIP3 signalling in neutrophils has recently been sug-
gested by the apparent competition between PIP3 and soluble inositol
pyrophosphates for common PH-domain effectors [136].
In nearly all of the above contexts of PI3K regulation it has been
extremely difﬁcult to tease apart the contributions of individual
elements in an in vivo context, because they are all interdependent e.g. ac-
tivation and recruitment are nearly always part of a self-regulated cycle.
15. Phagosome maturation
PI3P is generated on the cytoplasmic surface of endocytic structures
in all cells and appears just after severance from the plasmamembrane
in thephagosomes of neutrophils,macrophages and dendritic cells, irre-
spective of the size or content of the particle internalised or the initial
receptors engaged [78,137–139]. Where studied, it appears this PI3P is
generated by the recruitment of a Class III PI3K complex on the
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sequential dephosphorylation of the products of Class I PI3Ks cannot
be excluded. At least in one clear example, a Class IIIPI3K/p150/beclin
complex is recruited to the phagosome by the SLAM receptor, which
recognises components of the bacterial outer membrane [140].
This rise in PI3P acts to recruit and regulate the function of several
effectors important in phagosome maturation [78,137,141]. One of the
best studied of these is the p40phox subunit of the NADPH oxidase,
which is responsible for the efﬁcient recruitment of other oxidase sub-
units, leading to the generation of intra-phagosomal ROS [142,143].
This ROS plays an important role in the killing of some pathogens
(particularly bacteria and fungi) [144] and also contributes to appropri-
ate protease digestion of foreign proteins, yielding antigenic peptides
that can be loaded onto MHC-I (‘cross-presentation’) or MHC-II mole-
cules [145,146]. The in vivo signiﬁcance of this interaction is clear
from the phenotype of mice carrying an engineered mutation in the
PI3P-binding PX domain of p40phox [147] and also the discovery of a
human immunodeﬁciency patient who carries an analogous mutation
in their p40phox PX domain [148].
16. Autophagy
Autophagy is a major catabolic pathway mediating the encapsula-
tion of cytoplasmic components in a specialised double membrane
structure and their delivery to lysosomes. The initiation and course of
autophagy is regulated by Class III PI3K-containing complexes. In partic-
ular, the recruitment of an ATG14-containing Class III PI3K complex to
speciﬁc sites in the endoplasmic reticulum plays a critical role in the
induction of autophagy during starvation, a process in which the PI3P
effectors WIPI1/2 are thought to play a major role [81]. Whilst there
are still very few experiments that directly link Class III PI3K activity
to speciﬁc roles for autophagy in the immune response, there is an
increasing appreciation that autophagy does indeed play important
roles in several aspects of immune defence and inﬂammation.
There is a signiﬁcant and confusing literature that argues for an
important role for autophagy in the activation and clonal expansion of
lymphocytes after antigen recognition. This is at apparent odds with
themTORC1-regulated increase in anabolic pathways that accompanies
this process (mTORC1 is normally a powerful inhibitor of autophagy),
though recent evidence suggests that the induction of autophagy may
actually be more closely correlated to the cessation of clonal expansion
and the generation of memory cells [149].
It is also becoming increasingly apparent that autophagy may be an
important mechanism that is used by many different types of cells to
recognise and deliver viruses and intracellular bacteria to lysosomes,
resulting in their removal. This process is driven by the recognition of
speciﬁc ‘eat me’ signals that allow foreign molecules to be speciﬁcally
targeted to the autophagosome compartment, possibly an ancient
layer in the innate immune response [150].
As a consequence of delivering material for lysosomal degradation,
autophagy can also generate antigenic peptides for loading onto MHC-
II. Thus autophagy may play a signiﬁcant role in shaping the CD4+
T cell repertoire, both during the creation of self-tolerance and dur-
ing the induction of an effective T cell response against pathogens
or tumours (through the presentation of tumour-speciﬁc antigens)
[151–153].
One of the major hurdles to progress in deﬁning speciﬁc roles for
Class III or indeed Class II PI3Ks in immune-speciﬁc aspects of autophagy
is the lack of tools to interrogate their speciﬁc function in only one type
of complex, in isolation from other complexes in which they reside
(eg those involved in endosome regulation).
17. B cell functions
Class I PI3Ks are involved in the regulation of B cell development,
survival and activation by antigen [3,5,154]. Furthermore, switchingPI3K activity off appears to be as important as switching it on [3]. Devel-
opment of B cells to the pro-B cell stage requires IL-7R-dependent
signalling through Class I PI3Ks, though direct recruitment of Class IA
PI3Ks to the phosphorylated YXXM motif in the IL-7R is redundant
[155]. At this point, Class I PI3Ks are switched off to allow FOXO-
dependent transcription of the Rag genes and Ig heavy chain rearrange-
ment to form the pre-BCR [156,157]. Class I PI3K signalling through the
pre-BCR is then needed, in co-operationwith the IL-7R, to drive prolifer-
ation and growth of cells at the large pre-B cell stage [158]. Class I PI3K
activity is then switched off again, this time to allow FOXO-dependent
rearrangement of the light chains, forming the fully rearranged BCR
[156,157]. The strength of BCR-dependent PI3K signalling then contrib-
utes to both positive (‘clonal deletion’) and negative (‘anergy’) selection
strategies used to remove self-reactive clones and to generate functional
B cells destined for the periphery [159]. Immature B cells then leave
the bone marrow and differentiate into various mature B cell subsets
(follicular B cells, MZ- B cells and B1 cells) in the lymph nodes, spleen
and body cavities. Class I PI3Ks contribute to tonic BCR survival signals
that keep these naïve B cells alive as they search for cognate antigen
[158,160,161]. A patient with a homozygous premature stop codon
in the p85α gene has a complete lack of mature B cells, illustrating
the central importance of this pathway in B cell development [162].
Mice lacking both PI3Kα and δ in their B cell lineage exhibit a severe
defect in B cell development, with substantially reduced populations
of all peripheral B cells [161]. Mice lacking only PI3Kδ exhibit highly
reduced MZ-B and B1 cell populations and a smaller reduction in fol-
licular B cells, suggesting PI3Kδ plays a particularly important role in
the ﬁnal differentiation to MZ-B and B1 lineages or to their homing/
survival in their specialised niches [161]. Mice lacking functional
PI3Kδ produce substantially fewer natural antibodies, as would be
expected from their decreased populations of MZ-B and B1 cells
[91,92,163].
The activation of naïve B cells by antigen induces clonal expansion
and differentiation into antibody-producing plasma cells and there
is now a substantial body of data indicating Class I PI3Ks can play a
positive role in the signalling induced by the BCR and its co-receptors
driving both T cell-independent and T-cell dependent differentiation
[3,5,154,158]. Further, Class I PI3Ks play a role in suppressing AID-
dependent class switch recombination and afﬁnity maturation during
the germinal centre response [164].
The immediate signalling pathways downstream of the pre-BCR, the
fully rearranged BCR, and their various co-receptors (e.g. CD19, CD40)
are driven by several protein tyrosine kinases [154,158]. Key amongst
these are Src family kinases, which phosphorylate ITAMmotifs in recep-
tor chains, driving the recruitment and activation of Syk, and, indirectly,
BTK. These tyrosine kinases and their substrates create complex, self-
organising structures that are designed to read out the level, context
and duration of stimulation [158]. The individual details of these signal-
ling complexes at any particular moment in time are difﬁcult to ascer-
tain but some key features have emerged. BCR activation drives Class
IA PI3K recruitment to phosphorylated YXXM motifs on CD19 and
BCAP [165] and the PIP3 produced plays a signiﬁcant role in promoting
BTK-dependent phosphorylation and activation of PLCγ, thus regulating
Ins(1,4,5)P3/Ca2+ and DAG/PKCβ signals important for cell prolifera-
tion and cytokine synthesis [158,166]. Class I PI3K activation of PKB,
the activation of mTORC1 and the inhibition of GSK3 also play promi-
nent roles in antigen-stimulation of B cell clonal expansion [158]. The
signalling adaptor BLNK (SLP-65) co-ordinates signalling complex
formation downstream of the pre-BCR but is also responsible for limit-
ing the activation of PKB; this may be an important element in allowing
FOXO-mediated transcription of Rag1/2, IL-7R, Bcl-6 and BLNK itself
during B cell development [158,167,168]. PTEN plays an important
role in limiting the scale of PI3K signalling throughout the B cell lineage
e.g. [159] and the direct recruitment of SHIP1 to ITIM motifs in the
inhibitory FcγRIIB receptor plays an important role in setting the
threshold of B cell activation [169].
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Class IA PI3K isoform in BCR-driven signalling [3,5,91,92,170]. It is,
therefore, perhaps surprising that T cell-dependent antibody responses
are only modestly reduced in mice lacking functional PI3Kδ [91,92,163,
171,172]. Further, the main role for PI3Kδ seems to be in providing Th
cell help to B cells, rather than in the B cells themselves [173]. It seems
likely that redundant pathways of activation involving other receptors
(e.g. IL-4R, CD40, TLRs) are able to support antigen-induced BCR signal-
ling and induce an effective germinal centre response in vivo in the
absence of PI3Kδ [5]. It is also possible that the lack of PI3Kδ activity
may suppress Treg function, counterbalancing a reduction in the activa-
tion of follicular B cells. PI3Kδ is also the major PI3K isoform inhibiting
class switch recombination during the germinal response, meaning
T-cell dependent antibody responses are reduced in PI3Kδ-deﬁcient
mice and skewed towards IgE [174].
The signiﬁcant role of PI3Kδ in regulating B cell survival and prolifer-
ation guided the development of the PI3Kδ-selective inhibitor idelalisib
(also known as CAL-101 or GS-1101), which has recently received FDA
approval for the treatment of chronic lymphocytic leukaemia (CLL) and
non-Hodgkin’s lymphoma (iNHL) [175]. The results of early clinical
trials have been very promising but further work has suggested a
surprising mechanism of action, indicating idelalisib not only inhibits
BCR-dependent survival pathways but also both the production and
response to chemokines that serve to retain CLL cells in their protective
lymph node microenvironments [175,176].
18. T cell-dependent functions
Class I PI3Ks play important roles in T cell development, survival,
proliferation and differentiation that are in many ways analogous to
those in B cells, though they differ in signiﬁcant detail. PI3Kδ is again
the main Class IA PI3K engaged by complex protein tyrosine pathways
downstream of antigen receptor (TCR) signalling but important roles
for PI3Kγ have also been identiﬁed downstream of Gi-coupled chemo-
kine receptors [3,5]. PI3K-regulated outputs include PKB-dependent ac-
tivation of mTORC1/2 and CARMA-Bcl10, the up-regulation of nutrient
receptors, ITK-dependent regulation of PLCγ, activation of STAT and
NFκ-B and the inhibition of FOXOs [3,5,177–180]. An interesting feed-
back loop has also been described based on PLCγ-catalysed synthesis
of Ins(145)P3, iptk-dependent phosphorylation to Ins(1345)P4 and
the binding of Ins(1345)P4 to the PH domain of ITK, promoting PIP3-
driven recruitment of ITK oligomers to the membrane [181].
Mice lacking either functional PI3Kδ or PI3Kγ have only minor
defects in T cell development, while mice lacking both isoforms have
signiﬁcantly blocked transition through the CD4-CD8- stage (rearrange-
ment of the TCR β chain) and reduced survival of CD4+CD8+ cells
(rearrangement of the TCR α chain) [3,5,182,183]. In this process
PI3Kδ acts downstream of the pre-TCR and PI3Kγ acts downstream of
the Gi-coupled CXCR4 receptor (requiring inputs from both p101 and
the RBD of 110γ) [184,185]. Class III PI3K has also be shown to have
an important role in T cell development through regulating the surface
expression of the IL-7R [186].
Class I PI3Ks feature in the signalling pathways stimulated by the
engagement of naive CD4+ cells by antigen/MHC-II loaded APCs and
several lines of evidence suggest they are required to drive normal
proliferation and differentiation towards the different Th effector
subsets [3,5]. Thus, inhibition of PI3K signalling is variably associated
with reduced Th1, Th2, Th17 and Tfh responses [187–189]. PI3Kδ
appears to play the most prominent role [187,190,191], with additional
roles for PI3Kγ [192]. CD28 is an important co-receptor for the TCR and
possesses a YXXMmotif, but this does not appear to be a non-redundant
signal for Class IA PI3K recruitment [191]. PI3Kδ is required to produce a
maximal germinal centre response [173], and here there appears to be a
clear role for the co-receptor ICOS in driving direct recruitment of Class
IA PI3Ks to its phosphorylated YXXM motif and stimulating sufﬁcient
PI3K activation to support Tfh function [193]. PI3Kγ is involved insupporting chemokine-induced homing and trafﬁcking of CD4+ effector
cells to sites of inﬂammation [194].
Class I PI3Ks play a less important role in the activation and prolifer-
ation of CD8+ cells after encounterswith antigen/MHC-I [195]. However,
PI3K/PKB signalling is important for initiating the transcription pro-
gramme required for mature CTL function (including the expression of
granzyme and perforin) and the inhibition of FOXO-mediated transcrip-
tion of genes that is required for retention of CD8+ cells in lymph nodes
(CD62L, KLF2, CCR7 and S1P1) [195,196]. There is evidence that the
PI3Kγ isoform is required for CTL chemotaxis and trafﬁcking to sites of
infection [197].
A role for Class I PI3Ks in the development and function of Tregs has
also emerged [198]. Mice lacking functional PI3Kδ have increased num-
bers of Tregs in the thymus but reduced numbers in the periphery [199].
This may be a consequence of enhanced FOXO-mediated transcription
of Foxp3, a critical transcription factor in deﬁning Treg identity and sur-
vival [200,201]. Here, high PTEN expression may be required to limit
Class I PI3K signalling and allow Foxp3 to drive naïve T-cells towards
the Treg lineage [201,202]. Importantly however, Tregs lacking PI3Kδ
do not escape and survive in the periphery and are inefﬁcient suppres-
sors of T-cell proliferation, suggesting PI3Kδ is required for their
homing, survival and function [199].
So, the net effect of PI3Kδ inhibition on the adaptive immune system
is confusing with several conﬂicting aspects. Overall, PI3Kδ is required
for maximally effective humoral and cell-mediated immune responses
but it is also required for effective Treg function. The potential impor-
tance of PI3Kδ in Tregs is nicely illustrated by a recent study showing
that mice lacking functional PI3Kδmount an enhanced immune attack
on solid tumours; here the reduction in Treg function and enhanced
CTL-mediated tumour killing is suggested to outweigh a reduction in
the cell-autonomous function of the CTLs themselves [203]. Another
example is that mice lacking functional PI3Kδ show enhanced clearance
of Leishmaniamajor, despite reduced Th1 responses, also possibly due to
reduced Treg function [204]. Further, mice lacking functional PI3Kδ
seem susceptible to autoimmune colitis when housed under animal
house conditions [92]. Thus, the overall effect of PI3Kδ inhibition on
T cell responses is likely to be highly context dependent.
19. Potential therapeutic opportunities
Given the central role of a dysregulated and over-active inﬂammato-
ry response in many different human pathologies, and the important
roles uncovered for PI3Ks in promoting inﬂammation, many studies
have now investigated the effects of genetic or pharmacological inhibi-
tion of PI3K isoforms in mouse models of inﬂammatory disease
(Table 2) [1,2,4,5,87,205,206]. There are difﬁculties in interpreting the
results from these models, partly because in most cases the cause of
the human immune condition is still unclear and hence the validity
of the mouse model can be questioned, partly because mouse and
human immune systems sometimes appear to behave differently
(for example, in several of themousemodels of RA, neutrophilic inﬁltra-
tion is much more prominent than in the human disease) and partly
because genetic ablation can create developmental defects which com-
promise an assessment of mature cell function. Nonetheless, they do
represent opportunities to test the idea that single or combined inhibi-
tion of Class I PI3K isoformsmight confer resistance to different types of
chronic inﬂammation. This is particularly the case with the so called
‘effector-phase’ models, where the effects of the ‘passive’ transfer of
disease-inducing serum are modelled, rather than complex underlying
causes of the disease itself (such as loss of tolerance). On the whole,
the results have been promising (Table 2): mice lacking PI3Kγ activity
are resistant to models of SLE [207], RA [208,209], EAE [210], allergic
asthma [129], systemic anaphylaxis [77] and cardiovascular disease
[115,211]; mice lacking PI3Kδ activity are resistant to models of RA
[212], EAE [213], allergic asthma [127,128,214] and cutaneous hyper-
sensitivity [123]; mice lacking PI3Kβ activity are resistant to a model
Table 2
Examples of mouse models of chronic inﬂammatory disease in which the involvement of
Class I PI3K isoforms has been evaluated.


















Type-I diabetes PI3Kγ [234]
Atherosclerosis PI3Kγ [115]
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acquisita (EBA) [76]. Asmight be predicted from their overlapping func-
tions in inﬂammatory processes, mice deﬁcient in both PI3Kγ and δ
[212,215] or both PI3Kβ and δ [76] are more protected in a model of
RA than mice lacking the individual PI3K isoforms. It should be noted
that these mouse models are studied under ‘clean’ animal house condi-
tions and hence the extent to which PI3K inhibition might lead to
reduced resistance to infection is difﬁcult to predict. In this regard
mice lacking PI3Kγ can show increased susceptibility to some infections
e.g. impaired resolution to pneumococcal infection [216] or impaired re-
sistance to vaccinia virus [197]. Further, as described above, mice lack-
ing functional PI3Kδ can show increased IgE-mediated eosinophilia
and inﬂammation [172,174,190], but the extent to which this might
be transferred to humans is unclear.
The recent discovery of activatingmutations in the p110δ subunit in
a group of primary immune deﬁciency patients both illustrates the
importance of this isoform in the immune system and indicates some
major gaps in our understanding [217,218]. These patients suffer recur-
ring infections of the respiratory tract. They possess dominant muta-
tions in p110δ that are analogous to oncogenic mutations in the
kinase domain of p110α. These mutations result in enhanced binding
of p110δ to the membrane and enhanced activity. In agreement, PIP3
levels in primary T cells from these patientswere found to be signiﬁcantly
elevated. These patients exhibit distorted B and T cell differentiation and
modestly reduced and skewed antibody responses, but a coherent expla-
nation of their phenotype is still some distance away. Whatever the
mechanism however, these patients are clearly candidates for treatment
with PI3Kδ-selective inhibitors, such as those currently in development
for the treatment of B-cell lymphomas (see above) [219].20. Concluding remarks
Ahuge amount ofwork still remains to be done to reconcile informa-
tion gained in studying PI3K signalling in simple in vitro models of
immune cell function (i.e. simple regimens of agonist stimulation,
often involving non-primary cells) with complex in vivo models of
inﬂammation (i.e. involving multiple cell types with multiple stimuli
involved). This is particularly so in humans, where the capacity for ex-
perimentation is necessarilymore limited, though recent developments
in high throughput sequencing promise to yield further insights fromlinking polymorphisms and mutations in PI3K pathway components
to inﬂammatory disease.
However, we already know that for most of the in vivo processes
involved, the effects of selective Class I PI3K isoform inhibition are
usually partial. Speciﬁcally, we know that inhibition of PI3Kγ can
blunt recruitment and activation of innate immune cells, but this is
not complete; inhibition of PI3Kδ prevents a normal antibody response,
but some antibodies are made; inhibition of PI3Kδ and β can inhibit
antibody-dependent activation of neutrophils and macrophages, but
bacterial uptake and killing is relatively unscathed. Thus, the robust
and redundant processes that underlie the inﬂammatory response
may allow an opportunity to inhibit Class I PI3K-dependent processes
to a level where signiﬁcant alleviation of the pathology is possible but
sufﬁcient capacity in the immune system still remains. Moreover, the
tissue selective expression of PI3Kγ and δ in leukocytes offers the
opportunity to inhibit Class I PI3Ks in these cells without necessarily
incurringwidespread toxicity and organdamage. Thus far, initial studies
with mouse models of chronic inﬂammation appear to support this.
Further, the development of isoform-selective PI3K inhibitors by
academic and commercial laboratories has proceeded at pace, driven
largely by the promise of inhibiting cancer cell growth [87,205]. Several
potential drugs are now in clinical trials and the results from these
studies, particularly the development of the PI3Kδ-inhibitor idelalisib
(CAL-101), suggest ATP-site inhibitors do indeed have the potential to
turn into effective drugs,with little ‘off-target’ toxicity. The key question
then becomes: what singly- or multiply-selective PI3K inhibitors are
likely to prove most useful to treat which chronic inﬂammatory condi-
tions [61,87,215,220]? Arguments can be made in favour of δ, γ, γ/δ or
β/δ but in the end there is sufﬁcient uncertainty in extrapolation from
mouse models to human disease that a signiﬁcant effort to trial various
combinations in the best pre-clinical and clinical settings available
seems unavoidable.Acknowledgements
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